Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462629 · ClinicalTrials.gov registry record · Phase 1
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
A Phase 1 study of Central Nervous System Tumors, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02462629 is a Phase 1 study of Central Nervous System Tumors that has completed, run by Blaze Bioscience. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02462629, a Phase 1 study of Central Nervous System Tumors, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.
Conditions Studied
Interventions
- DRUG BLZ-100
Study Locations (1)
Washington
- Seattle Children's - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462629
The ClinicalTrials.gov registry entry for NCT02462629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blaze Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which BLZ-100 is the first listed.
NCT02462629 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT02462629 about?
NCT02462629 is a clinical study titled "Study of BLZ-100 in Pediatric Subjects With CNS Tumors". Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor...
What is the current status of trial NCT02462629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-06. Estimated completion is 2018-08.
What conditions does trial NCT02462629 study?
This clinical trial studies the following conditions: Central Nervous System Tumors.
What interventions are being tested in trial NCT02462629?
The interventions under investigation include: BLZ-100 (DRUG).
Who is sponsoring clinical trial NCT02462629?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462629 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.